drugset / Trial / NCT02259647
Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma
RandomizedParallel-groupDouble-blindTreatment
Summary
60 patients of radiological, biopsy proven advanced HCC (Hepatocellular carcinoma) patient will be randomized into two groups. Cases group will receive Sorafenib plus vitamin K and control group will receive Sorafenib plus placebo
Timeline
- Start
- 2014-10-01
- Primary completion
- 2015-10-31
- Completion
- 2015-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vitamin K | Unknown | 20 mg | Intravenous |
| Background | Sorafenib | Small molecule | 400 mg | — |